The Treatment of Anxiety and Depression with Medicinal Cannabis
"The Treatment of Anxiety and Depression with Medicinal Cannabis" will navigate through the scientific evidence surrounding the use of medicinal cannabis for treating anxiety and depression. Dr O’Brien and Dr Jayasuriya will discuss the current scientific evidence base around the use of medicinal cannabis for these conditions.
The session will also present two case studies, providing a practical perspective on treatment strategies. The aim is to clarify the types of cannabis medicines that are more appropriate for these conditions and provide a platform to discuss treatment strategies.
Dr Kylie O’Brien, Chief Scientific Officer of Cannim Group Pty Ltd, is an international expert on medicinal cannabis with a robust academic career in Chinese medicine. She has been a pivotal figure in Australia’s medicinal cannabis education and has authored books such as “Medicinal Cannabis and CBD in Mental Healthcare” and “A Clinician’s Guide to Integrative Oncology: What You Should Be Talking About with Cancer Patients and Why”.
In 2022, Kylie led an observational study investigating the effectiveness and safety of medicinal cannabis in Australians and has been a member of various committees and panels related to complementary medicines and education.
Dr Mihindu Jayasuriya, a graduate of Deakin University, has worked in various subsurgical specialties and spent considerable time in intensive care medicine and anaesthetics at The Royal Melbourne Hospital. He transitioned to working at Releaf Clinics due to his passion for cannabinoid medicine, where he is an Authorised Prescriber with the TGA for Medicinal Cannabis Products and serves as Chief Medical Officer (CMO) at Releaf Group Limited.
Subscribe to our Free Plan and gain access to this on-demand webinar plus four more, at no cost.
Claim 1 CPD hour
1 hour of recorded content
Statement of Attendance